Godavari Biorefineries Secures European Patent for Novel Anti-Cancer Pharmaceutical Composition
Godavari Biorefineries Ltd has successfully obtained a European patent for its "PHARMACEUTICAL COMPOSITION AND A PROCESS TO PREPARE THE SAME." The grant strengthens the company's intellectual property portfolio, specifically focusing on oncology treatments.The invention relates to a pharmaceutical composition that incorporates novel anti-cancer compounds alongside a solubilizing agent. The associated process is designed to prepare this composition. This innovation aims to significantly enhance the solubility and bioavailability of the active compounds, thereby boosting their therapeutic efficacy.
The composition holds crucial applications in the treatment of various cancers, including breast and prostate cancers. A key application highlighted by the invention is oral administration, which allows for improved patient management and treatment protocols. Furthermore, the patent covers the use of this pharmaceutical composition for the treatment and management of multiple types of cancer.
Key details regarding the European Patent are as follows:
| Detail | Information |
|---|---|
| Patent Number | EP4404920 |
| Patent Title | PHARMACEUTICAL COMPOSITION AND A PROCESS TO PREPARE THE SAME |
| Grant/Publication Date | 15.07.2026 |
| Patent Holder | Godavari Biorefineries Limited |
GODAVARIB Stock Price Movement
Shares of Godavari Biorefineries Limited are surging in live trading, climbing 5.12% or ₹12.30 to reach ₹252.40 as of 10:11 AM. The equity has traded 52,696 shares today, staying within the intraday range established between a low of ₹239.75 and a high of ₹254.05.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.